GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (LTS:0JGL) » Definitions » Shiller PE Ratio

PCI Biotech Holding ASA (LTS:0JGL) Shiller PE Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PCI Biotech Holding ASA Shiller PE Ratio Historical Data

The historical data trend for PCI Biotech Holding ASA's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Shiller PE Ratio Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PCI Biotech Holding ASA's Shiller PE Ratio

For the Biotechnology subindustry, PCI Biotech Holding ASA's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Shiller PE Ratio falls into.



PCI Biotech Holding ASA Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PCI Biotech Holding ASA's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, PCI Biotech Holding ASA's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.154/130.4000*130.4000
=-0.154

Current CPI (Jun. 2023) = 130.4000.

PCI Biotech Holding ASA Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.507 96.400 -0.686
201312 -0.686 96.600 -0.926
201403 -0.716 97.300 -0.960
201406 -0.729 97.500 -0.975
201409 -0.743 98.500 -0.984
201412 -0.917 98.600 -1.213
201503 -0.473 99.200 -0.622
201506 -0.306 100.100 -0.399
201509 -0.431 100.600 -0.559
201512 -0.390 100.900 -0.504
201603 -0.446 102.500 -0.567
201606 -0.576 103.800 -0.724
201609 -0.576 104.200 -0.721
201612 -0.408 104.400 -0.510
201703 -0.399 105.000 -0.496
201706 -0.260 105.800 -0.320
201709 -0.410 105.900 -0.505
201712 -0.640 106.100 -0.787
201803 -0.580 107.300 -0.705
201806 -0.280 108.500 -0.337
201809 -0.330 109.500 -0.393
201812 -0.050 109.800 -0.059
201903 -0.610 110.400 -0.721
201906 -0.710 110.600 -0.837
201909 -0.380 111.100 -0.446
201912 -0.682 111.300 -0.799
202003 0.120 111.200 0.141
202006 -0.780 112.100 -0.907
202009 -0.570 112.900 -0.658
202012 -0.710 112.900 -0.820
202103 -0.640 114.600 -0.728
202106 -0.490 115.300 -0.554
202109 -0.570 117.500 -0.633
202112 -1.250 118.900 -1.371
202203 -0.617 119.800 -0.672
202206 -0.394 122.600 -0.419
202209 -0.290 125.600 -0.301
202212 -0.180 125.900 -0.186
202303 -0.160 127.600 -0.164
202306 -0.154 130.400 -0.154

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PCI Biotech Holding ASA  (LTS:0JGL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PCI Biotech Holding ASA Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (LTS:0JGL) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (LTS:0JGL) Headlines

No Headlines